Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 451 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Reflux, Gastroesophageal Clear all
Active, not recruiting No phase listed Observational

Biological Sample Repository for Gastrointestinal Disorders

NCT05874726
View directory record Official record
Conditions
Obesity, Obesity, Morbid, Obesity, Primary, Gastro-Intestinal Disorder, Overweight and Obesity, Overweight, Overweight or Obesity, Diabetes Type 2, Diabetes Mellitus, Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemias, Sleep Apnea, GERD, Gastroesophageal Reflux, Musculoskeletal Pain Disorder, Cancer
Interventions
Blood Collection, Urine Collection, Tissue Sample Collection
Diagnostic Test
Lead sponsor
Pichamol Jirapinyo, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 17, 2026, 5:16 AM EDT
Completed No phase listed Observational

Registry of Outcomes From AntiReflux Surgery

NCT02923362
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Hiatal Hernia
Interventions
Laparoscopic Fundoplication, LINX Antireflux
Procedure · Device
Lead sponsor
The Heartburn Foundation
Other
Eligibility
21 Years and older
Enrollment
1,941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Mobile, Alabama • Heber Springs, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

The Effect of Positional Therapy on Symptoms of Gastroesophageal Reflux Disease: A Prospective Pilot Study

NCT04500288
View directory record Official record
Conditions
Gastro Esophageal Reflux
Interventions
LEFT Device
Device
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Not applicable Interventional

Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease

NCT00998244
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Overweight, Acid Reflux Disease
Interventions
Diet - very low carb or low fat
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2012 · Synced Sep 17, 2026, 5:16 AM EDT
Recruiting No phase listed Observational

The Role of Laryngopharyngeal Reflux in IPF

NCT03418350
View directory record Official record
Conditions
IPF, Reflux
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
40 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 3 Interventional

The Use of Lansoprazole to Treat Infants With Symptoms of Gastroesophageal Reflux

NCT00324974
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Lansoprazole microgranules suspension, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
1 Month to 11 Months
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
9
States / cities
Tampa, Florida • Park Ridge, Illinois • Shreveport, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2010 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Understanding the Pathophysiology and Effects of Diaphragmatic Breathing in Upright Gastroesophageal Reflux

NCT02972047
View directory record Official record
Conditions
GERD
Interventions
Diaphragmatic Breathing, Sham Comparator
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Sep 17, 2026, 5:16 AM EDT
Recruiting No phase listed Observational

Esophageal Cancer Risk Registry

NCT00260585
View directory record Official record
Conditions
Esophageal Cancer, Gastroesophageal Reflux Disease (GERD), Esophageal Diseases, Hiatal Hernia, Esophageal Achalasia
Interventions
Survey of client health, personal habits, family history, Blood specimen for non-DNA and DNA parts, Biopsy of esophageal/stomach tissue, lymph nodes, tumor, Biopsies, oral (saliva) and/or secretions, washings or mucosal scrapings/brushing from routine clinical surveillance endoscopies
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2050
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

NCT00321984
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
947 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
153
States / cities
Alabaster, Alabama • Birmingham, Alabama • Hueytown, Alabama + 150 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 4 Interventional

Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux

NCT00373997
View directory record Official record
Conditions
Larynx Disease, Gastroesophageal Reflux
Interventions
Esophageal and Laryngeal biopsies, egd with biopsy
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Not applicable Interventional Results available

Retrospective TIF Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study

NCT01327963
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Transoral Incisionless Fundoplication
Device
Lead sponsor
EndoGastric Solutions
Industry
Eligibility
18 Years to 85 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Ocala, Florida • Salem, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2Phase 3 Interventional

Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment

NCT00204698
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
Aciphex
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Sep 17, 2026, 5:16 AM EDT
Recruiting Phase 4 Interventional

Famotidine and Antacids for Treatment of Dyspepsia

NCT06241183
View directory record Official record
Conditions
Dyspepsia, GERD, Acid Reflux
Interventions
Intravenous Famotidine, Oral Maalox/ Mylanta
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Maintenance Intermittent Therapy for Symptomatic GERD Patients

NCT00165841
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Rabeprazole 20 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Vista, California
Source: ClinicalTrials.gov public record
Updated May 19, 2013 · Synced Sep 17, 2026, 5:16 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Fundoplication in Laparoscopic PEH Repair Based on FLIP

NCT05807763
View directory record Official record
Conditions
Paraesophageal Hernia
Interventions
Laparoscopic paraesophageal hernia repair without fundoplication
Procedure
Lead sponsor
The Foundation for Surgical Innovation and Education
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
2
States / cities
Evanston, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 17, 2026, 5:16 AM EDT
Not listed Phase 1Phase 2 Interventional

Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2

NCT04846010
View directory record Official record
Conditions
Sequelae of; Infection, Post Infection Glomerulonephritis, Post-Infectious Peripheral Neuralgia, Post-Infectious Disorder (Disorder), Post-Infectious Arthritis, Post-Infectious Polyneuritis, Post-Infectious Parkinsonism, Post-Infectious Hypothyroidism, Post Infectious Osteoarthritis, Anxiety Disorders, Depression, Depression, Anxiety, Depression, Bipolar, Insomnia, GERD, Gastro Esophageal Reflux, Hepatitis, Glomerulonephritis
Interventions
PurWet, FurFat, PurApo, PurPhl, PurClo, PurInf, Smoliv
Combination Product
Lead sponsor
All Natural Medicine Clinic, LLC
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers

NCT01101646
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
rabeprazole sodium
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 27, 2014 · Synced Sep 17, 2026, 5:16 AM EDT
Withdrawn Phase 4 Interventional

A New Nasopharyngeal pH Probe for Diagnosis of Laryngopharyngeal Reflux

NCT01308502
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
Dx-pH probe
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Month to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Not applicable Interventional

Tolerability Study of a Novel Microbiome Therapeutic in Subjects With Gastroesophageal Reflux Disease

NCT04491734
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
maltosyl-isomalto-oligosaccharides (MIMO)
Dietary Supplement
Lead sponsor
ISOThrive Inc.
Industry
Eligibility
25 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Manassas, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2021 · Synced Sep 17, 2026, 5:16 AM EDT
Terminated No phase listed Observational

Idiopathic Gastroparesis Registry Using a Predominant-Symptom Classification

NCT01173484
View directory record Official record
Conditions
Gastroparesis
Interventions
Not listed
Lead sponsor
University of Louisville
Other
Eligibility
16 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Not applicable Interventional Results available

Early Feasibility Study of the Neovasc Tiara™ Mitral Valve System

NCT02276547
View directory record Official record
Conditions
Mitral Valve Regurgitation
Interventions
Mitral valve replacement
Device
Lead sponsor
Shockwave Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 4 Interventional

The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia

NCT00926276
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Bronchopulmonary Dysplasia
Interventions
Fundoplication
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
24 Weeks to 1 Year
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 17, 2026, 5:16 AM EDT
Completed Phase 3 Interventional

Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

NCT00171418
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Timeline
2003 – 2005
U.S. locations
2
States / cities
Metairie, Louisiana • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 27, 2008 · Synced Sep 17, 2026, 5:16 AM EDT